calpeptin has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agou, F; Brownridge, P; Bryne, DP; Chakrabarti, LA; Chiaravalli, J; Craik, CS; Daly, LA; Emmott, E; Eyers, CE; Eyers, PA; Gambin, Y; Gellenoncourt, S; Grauslys, A; Jones, AR; Meyer, B; Sierecki, E; Verdin, E; Vignuzzi, M; Walter, M | 1 |
| Beck, T; Betzel, C; Böhler, H; Botosso, VF; Brehm, W; Chapman, HN; Cox, R; de Araújo, MV; de Oliveira, DBL; de Souza, EE; Drag, M; Durigon, EL; Ebert, G; Ewert, W; Falke, S; Filho, AFS; Flórez-Álvarez, L; Giaretta, PR; Guimarães, AMS; Günther, S; Hauser, M; Heinemann, MB; Herrmann, A; Hinrichs, W; Kapronezai, J; Karničar, K; Latham, SL; Lieske, J; Lindič, N; Loboda, J; Meents, A; Rahmani Mashhour, A; Reinke, PYA; Rut, W; Santelli, GMM; Sekirnik, A; Seychell, B; Silva-Pereira, TT; Tavares, MS; Turk, D; Usenik, A; Wrenger, C | 1 |
2 other study(ies) available for calpeptin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.
Topics: Animals; Antiviral Agents; Cell Line; COVID-19; COVID-19 Drug Treatment; Dipeptides; Humans; Mutation; Myosin-Light-Chain Kinase; Protease Inhibitors; Proteolysis; Proteomics; RNA, Small Interfering; SARS-CoV-2; src-Family Kinases; Viral Proteases; Viral Proteins; Virus Internalization; Virus Replication | 2021 |
Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections.
Topics: Antiviral Agents; Cathepsins; COVID-19; Cysteine Endopeptidases; Humans; Protease Inhibitors; SARS-CoV-2 | 2023 |